Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Accounts Payables (2020 - 2025)

Historic Accounts Payables for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $6.9 million.

  • SAB Biotherapeutics' Accounts Payables fell 43.22% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 43.22%. This contributed to the annual value of $5.5 million for FY2024, which is 1821.75% down from last year.
  • As of Q3 2025, SAB Biotherapeutics' Accounts Payables stood at $6.9 million, which was down 43.22% from $7.1 million recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Accounts Payables high stood at $12.5 million for Q4 2021, and its period low was $5.1 million during Q2 2024.
  • Moreover, its 5-year median value for Accounts Payables was $6.9 million (2024), whereas its average is $7.7 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first skyrocketed by 6872.5% in 2021, then crashed by 4822.88% in 2023.
  • Over the past 5 years, SAB Biotherapeutics' Accounts Payables (Quarter) stood at $12.5 million in 2021, then dropped by 20.38% to $9.9 million in 2022, then tumbled by 32.52% to $6.7 million in 2023, then fell by 18.22% to $5.5 million in 2024, then increased by 25.16% to $6.9 million in 2025.
  • Its last three reported values are $6.9 million in Q3 2025, $7.1 million for Q2 2025, and $6.1 million during Q1 2025.